“beta-thalassemia” Archives

in
Entry Author Date Location
Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More 04/10/20 National
AstraZeneca Joins RNAi Mix, Pledging $80M to Silence Therapeutics 03/25/20 Europe
Imara Dives Into Coronavirus-Churned Financial Waters With a $75M IPO 03/12/20 Boston
Imara Reveals IPO Plan as Sickle Cell Drug Advances in the Clinic 02/18/20 Boston
Third Time’s the Charm as Acceleron Drug Shows Early Promise in PAH 01/28/20 Boston
La Jolla Pharma’s Share Price Halves On Trial End, CEO Departure 11/26/19 San Diego
Bio Roundup: So Long Celgene, RNAi’s Arrival, Pharma in 2020 & More 11/22/19 National
Anemia Drug From Acceleron Pharma and Celgene Wins FDA Approval 11/08/19 New York
Beam Therapeutics Preps IPO and Sheds Light on Its Gene-Editing Drugs 09/27/19 Boston
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further 09/23/19 Boston
Challenging CRISPR, Trucode Raises $34M for New Gene-Editing System 09/10/19 San Francisco
Vertex Bets $950M on Semma and a Stem Cell Therapy for Diabetes 09/03/19 Boston
Bluebird Bio Sets $1.8M Price on Gene Therapy for Rare Blood Disease 06/14/19 Boston
Bio Roundup: ASCO Wrap, Bluebird’s EU Tap, CRISPR Baby Risk & More 06/07/19 National
Bluebird Bio’s Gene Therapy for Blood Disease Wins European Approval 06/03/19 Boston
Vertex Continues Plan to Diversify, Strikes a $70M Pact With Kymera 05/15/19 Boston
ElevateBio Gets $150M to Grow a Crop of Gene & Cell Therapy Startups 05/13/19 Boston
Celgene Files for FDA Approval of Blood Disease Drug 04/05/19 New York
Panel Nod Moves Bluebird’s Gene Therapy Closer to Europe’s Market 03/29/19 Boston
With $100M MeiraGTx Deal, J&J Signals Bigger Move Into Gene Therapy 01/31/19 New York
ASH 2018: Three Up, Two Down as Big Blood Disease Meeting Rolls On 12/03/18 National
Bio Roundup: CRISPR Babies, Blood Diseases, Big Cancer Nod & More 11/30/18 National
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More 11/26/18 National
Orchard, Fueled by GSK’s Ex-Gene Therapy Biz, Nets $200M in IPO 10/31/18 Boston
Vertex Hums Along as AbbVie Snatches Up a Rival’s CF Drugs for $45M 10/25/18 Boston
CRISPR Therapeutics, Vertex Get FDA Green Light for Sickle Cell Test 10/10/18 Boston
Acceleron, Celgene Drug Shines in Phase 3 Test in Rare Blood Disorder 07/09/18 Boston
Acceleron’s Blood Drug Hits Phase 3 Goals, Paves Way for FDA Filing 06/28/18 Boston
Sarepta’s Data Are First in Rush for Duchenne Gene Therapy 06/19/18 Boston
For Sickle Cell, a Complex Disease, New Drugs Could Bring Complex Costs 06/15/18 San Francisco
Page 1 of 4 next page »